Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

http://www.businessweek.com/stories/2004-08-31/first-albany-ups-supergen-to-buy

Markets & Finance

First Albany Ups Supergen to Buy


First Albany upgraded Supergen (SUPG) to buy.

Analyst Lucy Lu says she's upgrading from neutral as MGI Pharmaceuticals licensed the worldwide rights to Supergen's anti-cancer therapeutic Dacogen. She notes MGI will make a $40 million equity investment in Supergen and pay up to $45 million in regulatory milestones and royalties of 20% to 30% based on Dacogen sales.

Lu says MGI is the ideal partner for Dacogen; she cites its sales force and the successful commercialization of Aloxi, an oncology supportive care product. With MGI on board, Lu sees Dacogen becoming a more significant part of Supergen's valuation. She cut the $1.62 2004 loss estimate to a $1.57 loss, and trimmed the $1.03 2005 loss to a 78-cent loss.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus